SABS - SAB Biotherapeutics, Inc.
IEX Last Trade
4.19
0 0%
Share volume: 134
Last Updated: Thu 26 Dec 2024 05:56:41 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$4.19
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-10 | 2022-11-14 | 2023-04-14 | 2023-05-15 | 2023-08-21 | 2023-11-13 | 2024-03-29 | 2024-05-20 | |
| Total revenue | 6.351 M | 3.590 M | 2.161 M | 581.101 K | 85.518 K | 1.267 M | 305.011 K | 944.575 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 6.351 M | 3.590 M | 2.161 M | 581.101 K | 85.518 K | 1.267 M | 305.011 K | 944.575 K | |
| -43.47% | -39.80% | -73.11% | -85.28% | 1,381.98% | -75.93% | 209.69% | |||
| Operating expenses | 12.893 M | 11.397 M | 10.021 M | 7.983 M | 6.562 M | 6.590 M | 19.179 M | 12.335 M | |
| Selling general and admin | 4.309 M | 4.044 M | 2.844 M | 3.447 M | 2.900 M | 2.571 M | 14.881 M | 4.189 M | |
| Research and development | 8.584 M | 7.353 M | 7.177 M | 4.536 M | 3.662 M | 4.020 M | 4.297 M | 8.146 M | |
| Total expenses | 12.893 M | 11.397 M | 10.021 M | 7.983 M | 6.562 M | 6.590 M | 19.179 M | 12.335 M | |
| -11.61% | -12.07% | -20.34% | -17.80% | 0.43% | 191.02% | -35.68% | |||
| Operating income | -6.543 M | -7.807 M | -7.860 M | -7.402 M | -6.477 M | -5.323 M | -18.874 M | -11.391 M | |
| Ebit | -6.543 M | -7.807 M | -7.860 M | -7.402 M | -6.477 M | -5.323 M | -18.874 M | -11.391 M | |
| Pretax income | -4.868 M | -7.076 M | -7.849 M | -7.354 M | -6.881 M | -5.102 M | -22.857 M | -5.026 M | |
| 45.35% | 10.92% | -6.31% | -6.43% | -25.85% | 347.97% | -78.01% | |||
| Income tax | -92.281 K | 0.000 | 25.629 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -4.776 M | -7.076 M | -7.875 M | -7.354 M | -6.881 M | -5.102 M | -22.857 M | -5.026 M | |
| -48.16% | -11.29% | 6.61% | 6.43% | 25.85% | -347.97% | 78.01% | |||
| Net income | -4.776 M | -7.076 M | -7.875 M | -7.354 M | -6.881 M | -5.102 M | -22.857 M | -5.026 M | |
| -48.16% | -11.29% | 6.61% | 6.43% | 25.85% | -347.97% | 78.01% |